SCHEMBL12673256

SCHEMBL12673256

O=C(Nc1cccc2[nH]c(-c3cccc(C(F)(F)F)c3)nc12)c1nccs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.54
▸ GRIN1 Q05586 1/20 0.45
▸ GRIN2B Q13224 1/20 0.45
▸ STK33 Q9BYT3 1/20 0.45
▸ PIN1 Q13526 1/20 0.42
▸ RXFP1 Q9HBX9 2/20 0.41
▸ TLR7 Q9NYK1 1/20 0.40
▸ SCN2A Q99250 1/20 0.40
▸ KIT P10721 2/20 0.40
▸ MEN1 O00255 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12673259 0.83 PARP1 (0.57) PARP1STK33PIN1RXFP1TLR7
SCHEMBL1895860 0.81 PARP1 (0.54) PARP1PIN1RXFP1TLR7MEN1
SCHEMBL12673116 0.81 PARP1 (0.62) PARP1RXFP1NPC1RAB9AALDH1A1
SCHEMBL12673172 0.81 PARP1 (0.54) PARP1PIN1TLR7KITALDH1A1
SCHEMBL12673112 0.80 RXFP1 (0.58) PARP1RXFP1KITMEN1KMT2A
SCHEMBL12673319 0.77 PARP1 (0.61) PARP1RXFP1MEN1NPC1RAB9A
SCHEMBL12673126 0.75 PARP1 (0.68) PARP1PIN1RXFP1
SCHEMBL3695865 0.74 PARP1 (0.47) PARP1PIN1MEN1NPC1RAB9A
SCHEMBL1895383 0.74 PARP1 (0.54) PARP1PIN1NPC1RAB9ACNR2
SCHEMBL12673307 0.73 PARP1 (0.64) PARP1PIN1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2315763-B1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-06-01 — — EP disclosed
US-20150057272-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2015-02-26 — — US disclosed
US-20110124637-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-05-26 — — US disclosed
WO-2010003048-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124637-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 PARP1 287/4885GRIN1 3360/4885GRIN2B 3613/4885
US-20150057272-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 PARP1 331/4885GRIN1 3778/4885GRIN2B 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback